Biosimilars

(Picture credit: Joe Flintham/flickr)

J&J and EGA differ on safety impact of same INNs for biosimilars

By Fiona Barry

Johnson & Johnson (J&J) has called on the US FDA to prevent biosimilars being given the same non-proprietary names as their original biologics, while the European Generics Association maintains the practice is “proven to be safe” and “supported...

Cobra Biologics moves to beef up mAb capacity

Cobra Biologics moves to beef up mAb capacity

By Gareth Macdonald

Corba Biologics has opted for a HyClone bioreactor to boost its antibody production capacity citing customer demand and biosimilars as the drivers for the investment.

Biosimilars: Is the Market Getting Too Much Attention?

Biosimilars: Is the Market Getting Too Much Attention?

By Zachary Brennan

As anticipation swells over how the biosimilar market will shape up in the US, some contract biologic manufacturing executives don’t seem to think the size of the market is worth all of the hype yet.